FOUND: 5 | Mind Blowing Facts

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy

On Thursday, Johnson Johnson (NYSE:JNJ) announced positive topline results from a recent study.

Benzinga · Oct 16, 2025

Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link

High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public

The Guardian - UK · Oct 16, 2025

The Real Reason Johnson & Johnson Switched to Corn Starch — Too Late to Save Its Reputation?

Johnson & Johnson's belated shift from talc to corn starch in its baby powders came amid mounting litigation—but can it repair the damage to its reputation?

International Business Times UK · Oct 16, 2025

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Johnson Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.

Benzinga · Oct 15, 2025

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

On Tuesday, Johnson Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

Benzinga · Oct 15, 2025

Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off

Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.

MarketBeat · Oct 15, 2025

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Johnson Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.

Benzinga · Oct 14, 2025

Goldman Sachs, JPMorgan Chase And 3 Stocks To Watch Heading Into Tuesday

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Benzinga · Oct 14, 2025

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Health care giant Johnson Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.

Benzinga · Oct 13, 2025

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

The Food and Drug Administration (FDA) has updated safety labeling for Johnson Johnson's (NYSE:JNJ) Carvykti after receiving reports of immune effector cell-associated enterocolitis (IEC-EC)—a rare but serious complication seen in both clinical trials and postmarketing data.

Benzinga · Oct 13, 2025